Janux Therapeutics (JANX) closed out FY 2025 with Q4 revenue of US$0 and a basic EPS loss of US$0.51, keeping the focus squarely on how efficiently it is funding and progressing its pipeline rather than on top line growth. The company has seen quarterly revenue move between US$0 and US$10 million over the past year, while basic EPS losses have ranged from US$0.38 to US$0.55 per share. This sets up a story in which any potential upside depends heavily on whether management can convert this spend into healthier margins.

See our full analysis for Janux Therapeutics.

With the headline numbers on the table, the next step is to see how these results line up against the widely held narratives around Janux’s growth potential, risk profile and long term earnings path.

Losses Stack Up To US$113.6 Million Over The Year

• On a trailing 12 month basis to Q4 FY 2025, Janux booked a net loss of US$113.6 million and a basic EPS loss of US$1.83, compared with a trailing net loss of US$68.9 million and basic EPS loss of US$1.28 at Q4 FY 2024.
• Critics highlight that losses have grown about 30.3% per year over the past five years, and the latest trailing loss of US$113.6 million adds weight to that concern, yet the pattern within the year is not one way:
  • The quarterly net loss moved between US$23.5 million and US$33.9 million across FY 2025, so bears pointing to a simple straight line deterioration have to reckon with some quarter to quarter variation.
  • At the same time, earnings are forecast to decline about 9% per year over the next three years, which aligns with the history of growing losses rather than signaling an earnings improvement in the near term.

Curious how other investors connect Janux's growing losses with its future story and risk profile? 📊 Read the what the Community is saying about Janux Therapeutics.

Forecast 63.7% Revenue Growth Versus Ongoing Losses

• Revenue is forecast to grow about 63.7% per year while Janux remains unprofitable and is not expected to reach profitability over the next three years, with earnings forecast to decline about 9% per year over that period.
• Supporters of a more bullish angle often point to that forecast revenue growth, and the mix of recent numbers shows why this can sound appealing but also complicated:
  • Over the last year, trailing revenue figures shifted between US$0.4 million and US$13.0 million, and the latest trailing 12 month revenue sits at US$10 million, which supports the idea that there is some top line momentum to build on.
  • However, the same trailing period pairs that revenue base with a US$113.6 million loss, so anyone leaning on the bullish growth story has to accept that the current financial profile is still dominated by spending rather than by revenue.

Low 0.8x P/B With A Volatile Share Price

• Janux trades on a P/B of 0.8x, compared with a peer average of 2.8x and a US biotech industry level of 2.7x, while the share price around US$13.61 has been highly volatile over the past three months.
• Bears argue that the combination of persistent losses and forecast earnings decline justifies that lower multiple, and the recent data gives them some clear talking points:
  • The company is expected to remain loss making over at least the next three years and has already recorded a trailing net loss of US$113.6 million, so the low P/B can be read as investors pricing in that earnings drag.
  • Higher than market share price volatility over the last three months means the discount could widen or narrow quickly around any news, which is the kind of price behavior cautious investors focus on when they say the low P/B on its own is not enough.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Janux Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mixed tone of these results leaves you uncertain, take a moment to look through the numbers yourself and decide what they really signal for you, then weigh up the 1 key reward and 4 important warning signs before you firm up your view.

See What Else Is Out There

With losses of US$113.6 million over the year, ongoing EPS pressure and no clear path to profitability, Janux carries meaningful risk for cautious investors.

If that level of uncertainty feels uncomfortable, you might want to balance it by checking companies screened as more resilient, starting with 76 resilient stocks with low risk scores while you reassess your options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.